DYRK1A and diabetes mellitus: Numerous studies have previously reported the development of DYRK1A inhibitor scaffolds for a variety of therapeutic applications including diabetes [2,3,4,5,6,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33].